The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025) held in Amsterdam during March 19–22 highlighted transformative innovations in diabetes management. From automated insulin delivery (AID) advancements to AI-driven glucose monitoring and emerging cellular therapies, industry leaders showcased the future of diabetes care.
- The Impact of Early Automated Insulin Delivery (AID) Adoption
Key Development: Research presented at ATTD 2025 revealed that initiating AID systems at the time of type 1 diabetes (T1D) diagnosis in pediatric and adolescent populations significantly improves long-term outcomes, enhancing glycemic control and quality of life.
Growth Opportunities:
- Policy reforms encouraging early AID adoption in healthcare could accelerate market expansion.
- Expanded insurance and reimbursement policies are needed to improve AID accessibility for newly diagnosed children.
- Development of pediatric-specific AID systems designed for younger patients.
- Bridging the Gap: Diabetes Technology Adoption Among Young Adults
Key Development: A study found that individuals aged 18–23 in adult healthcare settings exhibit higher HbA1c levels and lower adoption of diabetes technology compared to their counterparts in pediatric care.
Growth Opportunities:
- Structured transition programs to guide young adults from pediatric to adult care can enhance technology adoption.
- Digital tools tailored to young adults could support improved diabetes management.
- Educational initiatives to promote the benefits of insulin pumps and continuous glucose monitoring (CGM) systems.
- Addressing DKA and Hypoglycemia Risks in CKD Patients
Key Development: Adults with both T1D and chronic kidney disease (CKD) showed an increased risk of diabetic ketoacidosis (DKA), while severe hypoglycemia rates remained stable.
Growth Opportunities:
- AI-powered glucose monitoring devices to predict and prevent DKA episodes.
- Development of insulin dosing algorithms customized for CKD patients.
- Tackling Healthcare Disparities in Diabetes and CKD
Key Development: Non-Hispanic Black individuals were found to be disproportionately affected by both T1D and CKD, emphasizing healthcare inequities.
Growth Opportunities:
- Community outreach initiatives to support underserved populations.
- Increased funding for research on health disparities in diabetes care.
- Development of culturally sensitive diabetes education programs.
- Advancements in Cellular Therapies for Type 1 Diabetes
Key Development: Research on beta cell replacement therapies by companies like Vertex and Project ACT demonstrated promising progress, though scalability and minimally invasive delivery remain challenges.
Growth Opportunities:
- Expedited regulatory pathways to accelerate therapy approval.
- Research to enhance cell therapy longevity and accessibility.
- Strategies for widespread affordability upon commercialization.
- The Future of AID Systems: Towards Fully Closed-Loop Solutions
Key Development: The next evolution in AID technology focuses on completely closed-loop systems requiring minimal user intervention. Dual-hormone pumps incorporating both glucagon and insulin are also under research.
Growth Opportunities:
- AI-driven insulin algorithms for adaptive dosing.
- Expansion of AID technology for type 2 diabetes (T2D).
- Development of discreet, wearable insulin delivery systems.
- The Rise of Continuous Ketone Monitoring (CKM)
Key Development: CKM is emerging as a potential early detection tool for DKA, with real-time ketone tracking offering better insights for high-risk patients.
Growth Opportunities:
- Clinical validation of CKM technology for widespread adoption.
- Integration with CGM systems for simultaneous glucose and ketone monitoring.
- Strengthening Early Detection and Intervention Strategies
Key Development: The conference underscored the importance of evidence-based screening programs for early diabetes and pre-diabetes detection.
Growth Opportunities:
- AI-powered risk assessment tools integrated into routine screenings.
- Public-private partnerships to scale community screening initiatives.
Industry Announcements from Leading Companies
- Dexcom: Showcased a 15-day CGM with improved accuracy and integration with NovoPen devices.
- Tandem Diabetes: Positive trial results for Control-IQ+ insulin pump use in T2D.
- Insulet: The RADIACT study confirmed the efficacy of Omnipod 5 in transitioning patients from multiple daily injections (MDI) to AID.
- Medtronic: Demonstrated the effectiveness of the Simplera CGM and InPen system in optimizing insulin dosing and maintaining time-in-range.
Looking Ahead: The Future of Diabetes Innovation
ATTD 2025 reinforced the industry’s commitment to advancing diabetes care through automation, AI-driven management, and equitable healthcare access. Key areas of focus include:
- Short-term (1 year): Increasing CGM accessibility and integrating AI-powered insulin automation.
- Mid-term (2-3 years): Expanding hybrid closed-loop AID systems and developing real-world data-driven personalized diabetes care.
- Long-term (5+ years): Achieving seamless device interoperability and advancing cellular therapies for T1D.
Want to Learn More?
Stay informed on the latest diabetes technology advancements by connecting with our industry experts at hello@frost.com.
